High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib

Brain metastases (BMs) and bone metastases seriously affect the prognosis of lung cancer patients. How to optimize the use of existing targeted drugs is an important way to address the clinical needs of the central nervous system in the individualized treatment of non-small cell lung cancer (NSCLC)....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang Ying, Zhang Xiaowen, Wang Fang, Feng Yan, Tang Huaping
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	lung adenocarcinoma cancer brain metastases bone metastasis exon 21 mutation t790m mutation osimertinib gefitinib Medicine R
Acceso en línea:	https://doaj.org/article/b6e0ac2177964adead41d36295725fc0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b6e0ac2177964adead41d36295725fc0
record_format	dspace
spelling	oai:doaj.org-article:b6e0ac2177964adead41d36295725fc02021-12-05T14:10:55ZHigh quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib2391-546310.1515/med-2021-0379https://doaj.org/article/b6e0ac2177964adead41d36295725fc02021-10-01T00:00:00Zhttps://doi.org/10.1515/med-2021-0379https://doaj.org/toc/2391-5463Brain metastases (BMs) and bone metastases seriously affect the prognosis of lung cancer patients. How to optimize the use of existing targeted drugs is an important way to address the clinical needs of the central nervous system in the individualized treatment of non-small cell lung cancer (NSCLC). In this report, we describe an NSCLC patient with BMs who survived for 58 months, which is the longest survival case among lung cancer patients with BMs. The patient was initially diagnosed with lung cancer more than 5 years ago with simultaneous brain, bone, and lung metastases. After gefitinib resistance, she received osimertinib in sequence with no progress for 58 months in total and maintained very good quality of life.Zhang YingZhang XiaowenWang FangFeng YanTang HuapingDe Gruyterarticlelung adenocarcinoma cancerbrain metastasesbone metastasisexon 21 mutationt790m mutationosimertinibgefitinibMedicineRENOpen Medicine, Vol 16, Iss 1, Pp 1602-1607 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	lung adenocarcinoma cancer brain metastases bone metastasis exon 21 mutation t790m mutation osimertinib gefitinib Medicine R
spellingShingle	lung adenocarcinoma cancer brain metastases bone metastasis exon 21 mutation t790m mutation osimertinib gefitinib Medicine R Zhang Ying Zhang Xiaowen Wang Fang Feng Yan Tang Huaping High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
description	Brain metastases (BMs) and bone metastases seriously affect the prognosis of lung cancer patients. How to optimize the use of existing targeted drugs is an important way to address the clinical needs of the central nervous system in the individualized treatment of non-small cell lung cancer (NSCLC). In this report, we describe an NSCLC patient with BMs who survived for 58 months, which is the longest survival case among lung cancer patients with BMs. The patient was initially diagnosed with lung cancer more than 5 years ago with simultaneous brain, bone, and lung metastases. After gefitinib resistance, she received osimertinib in sequence with no progress for 58 months in total and maintained very good quality of life.
format	article
author	Zhang Ying Zhang Xiaowen Wang Fang Feng Yan Tang Huaping
author_facet	Zhang Ying Zhang Xiaowen Wang Fang Feng Yan Tang Huaping
author_sort	Zhang Ying
title	High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
title_short	High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
title_full	High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
title_fullStr	High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
title_full_unstemmed	High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
title_sort	high quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/b6e0ac2177964adead41d36295725fc0
work_keys_str_mv	AT zhangying highqualityof58monthlifeinlungcancerpatientwithbrainmetastasessequentiallytreatedwithgefitinibandosimertinib AT zhangxiaowen highqualityof58monthlifeinlungcancerpatientwithbrainmetastasessequentiallytreatedwithgefitinibandosimertinib AT wangfang highqualityof58monthlifeinlungcancerpatientwithbrainmetastasessequentiallytreatedwithgefitinibandosimertinib AT fengyan highqualityof58monthlifeinlungcancerpatientwithbrainmetastasessequentiallytreatedwithgefitinibandosimertinib AT tanghuaping highqualityof58monthlifeinlungcancerpatientwithbrainmetastasessequentiallytreatedwithgefitinibandosimertinib
_version_	1718371623703150592

High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib

Ejemplares similares